[Guideline for diagnosis and management of metabolic dysfunction-associated fatty liver disease in primary care (2025)]. [PDF]
Zhonghua Gan Zang Bing Za ZhiChronic Disease Management Branch of China Medical Biotechnology Association +4 more
europepmc +1 more source
[Cajanonic acid A derivative XJ-60 improves liver fibrosis in mice with non-alcoholic fatty liver disease by inhibiting the SP1/TGF-β/Smad3 signaling axis]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoGeng Z +8 more
europepmc +1 more source
[Introduction of the key update points of the 2025 Canadian Association for the Study of the Liver guideline for the management of chronic hepatitis B]. [PDF]
Zhonghua Gan Zang Bing Za ZhiZhuang H.
europepmc +1 more source
[Clinical progress in stem cell therapy for end-stage liver disease]. [PDF]
Zhonghua Gan Zang Bing Za ZhiPan YF, Xie YB, Shi L, Shi M, Wang FS.
europepmc +1 more source
[<i>Hugan</i> Decoction alleviates non-alcoholic fatty liver disease in rats by activating the AMPK/m-TOR signaling pathway and reducing lipid synthesis]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoShang D, Li W, Cui L, Chen M.
europepmc +1 more source
[Reappraisal on the clinical diagnosis and treatment of hereditary liver diseases]. [PDF]
Zhonghua Gan Zang Bing Za ZhiJia JD.
europepmc +1 more source